Wedelolactone, a naturally occurring coumestan, enhances interferon-γ signaling through inhibiting STAT1 protein...

Area of Science:

• Molecular Biology
• Immunology
• Pharmacology

Background:

• Signal transducer and activator of transcription 1 (STAT1) is crucial for cellular responses to cytokines like IFN-γ, regulating genes involved in cell fate and migration.
• STAT1 activation, via phosphorylation by JAKs, is counteracted by dephosphorylation mediated by tyrosine phosphatases, notably T-cell protein tyrosine phosphatase (TCPTP).

Purpose of the Study:

• To investigate the effect of the natural compound wedelolactone on IFN-γ signaling and STAT1 regulation.
• To identify the specific mechanism by which wedelolactone modulates STAT1 activity and its potential therapeutic applications.

Main Methods:

• Investigated the impact of wedelolactone on IFN-γ-induced STAT1 phosphorylation and dephosphorylation.
• Determined wedelolactone's inhibitory effect on T-cell protein tyrosine phosphatase (TCPTP) activity and its binding site.
• Assessed the synergistic effect of wedelolactone and IFN-γ on tumor cell apoptosis.

Main Results:

• Wedelolactone was found to inhibit STAT1 dephosphorylation by specifically targeting TCPTP, thereby prolonging STAT1 activation.
• Wedelolactone directly interacts with the C-terminal autoinhibition domain of TCPTP.
• Wedelolactone demonstrated synergy with IFN-γ to induce apoptosis in tumor cells.

Conclusions:

• Wedelolactone represents a novel inhibitor of TCPTP, offering a specific mechanism to regulate protein tyrosine phosphatase activity.
• The findings suggest wedelolactone as a potential therapeutic candidate for cancers and other proliferation disorders due to its ability to enhance IFN-γ signaling and induce tumor cell death.